Reduction in Short-term Outpatient Consultations After a Campaign With Measles Vaccine in Children Aged 9-59 Months: Substudy Within a Cluster-Randomized Trial

J Pediatric Infect Dis Soc. 2020 Nov 10;9(5):535-543. doi: 10.1093/jpids/piaa091.

Abstract

Background: We assessed a measles vaccination campaign's potential short-term adverse events.

Methods: In a cluster-randomized trial assessing a measles vaccination campaign's effect on all-cause mortality and hospital admission among children aged 9-59 months in Guinea-Bissau, children received a measles vaccination (intervention) or a health check-up (control). One month to 2 months later, we visited a subgroup of children to ask mothers/guardians about outpatient consultations since enrollment. In log-binomial models, we estimated the relative risk (RR) of nonaccidental outpatient consultations.

Results: Among 8319 children (4437 intervention/3882 control), 652 nonaccidental outpatient consultations occurred (322 intervention/330 control). The measles vaccination campaign tended to reduce nonaccidental outpatient consultations by 16% (RR, 0.84 [95% confidence interval {CI}, .65-1.11]), especially if caused by respiratory symptoms (RR, 0.68 [95% CI, .42-1.11]). The reduction tended to be larger in children who prior to trial enrollment had a pentavalent vaccination (diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b) as the most recent vaccination (RR, 0.61 [95% CI, .42-.89]) than in children who prior to trial enrollment had a routine measles vaccination as the most recent vaccination (RR, 0.93 [95% CI, .68-1.26]) (P = .04 for interaction).

Conclusions: In the short term, a measles vaccination campaign seems not to increase nonaccidental outpatient consultations but may reduce them.

Clinical trials registration: NCT03460002.

Keywords: adverse events; beneficial nonspecific-effects; campaign; children; measles vaccine.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Child Mortality
  • Child, Preschool
  • Female
  • Guinea-Bissau
  • Hospitalization / statistics & numerical data*
  • Humans
  • Immunization Programs / methods*
  • Infant
  • Infant Mortality
  • Male
  • Measles / mortality
  • Measles / prevention & control
  • Measles Vaccine / adverse effects*
  • Measles Vaccine / therapeutic use
  • Outpatients
  • Referral and Consultation / statistics & numerical data*
  • Risk Factors
  • Vaccination

Substances

  • Measles Vaccine

Associated data

  • ClinicalTrials.gov/NCT03460002